PTGS2 and non-small cell lung carcinoma: However, unlike some previously reported studies which showed that COX-2 expression was most consistently associated with poorer survival among stage I and II NSCLC patients [38,39], our study neither showed the correlation of COX-2 expression with patient's survival nor prognostic value in early stage adenocarcinma [21].